samatasvir
Small moleculeexperimental
Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C. It was originally developed by Idenix, and development has been continued by Merck & Co. following their acquisition of Idenix. Samatasvir has shown good results in Phase II trials. — Wikipedia
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2011 (NCT01335607)
Timeline
Indications
Mechanism of action
- Hepatitis C virusINHIBITOR
Hepatitis C virus inhibitor
- Nonstructural protein 5AINHIBITOR
Nonstructural protein 5A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc2cc(-c3csc4c(-c5ccc(-c6c[nH]c([C@@H]7CCCN7C(=O)[C@H](NC(=O)OC)c7ccccc7)n6)cc5)csc34)ccc2[nH]1)C(C)C- Mol. weight
- 885.08 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSamatasvir ↗
- ChEMBLCHEMBL3039519 ↗
Also known as
- idx18719
- idx18719
- idx719
- idx719
- idx719
- samatasvir
- samatasvir
- samatasvir
- samatasvir
- samatasvir
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01919125 | Phase 1 | Aug 1, 2013 | Merck |
| NCT01907724 | Phase 1 | May 1, 2013 | Johnson and Johnson, Merck |
| NCT01852604 | Phase 2 | Mar 1, 2013 | Johnson and Johnson, Merck |
| NCT01813552 | Phase 1 | Feb 1, 2013 | Merck |
| NCT01813513 | Phase 1 | Jan 1, 2013 | Merck |
| NCT01508156 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2012 | Merck |
| NCT01335607 | Phase 1 | Apr 1, 2011 | Merck |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 7 | 7 | 2 | 2011 |
| Johnson and Johnson | For profit | 2 | 0 | 2 | 2013 |
2 organizations
Page 1 / 1